Biotechnology ecosystem company Alloy Therapeutics announced on Tuesday that it has entered into a multi-target collaboration and licence agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to advance antisense therapeutics using its proprietary AntiClastic ASO platform.

Under the terms of the agreement, Alloy will receive an upfront payment and is eligible for milestone payments and tiered royalties tied to resulting products.

The partnership combines Biogen's experience in developing innovative medicines with Alloy's antisense discovery capabilities, targeting multiple undisclosed programmes. Alloy's AntiClastic ASO platform is designed to improve potency and therapeutic index by enabling delivery to intracellular RNA targets, addressing historical limitations related to biodistribution and efficacy.

This collaboration builds on prior work between the companies, including Biogen's use of Alloy's AI-enabled transgenic mouse platform. Alloy said that its broader drug discovery ecosystem integrates advanced computational and AI-driven technologies to accelerate therapeutic development.

The AntiClastic ASO platform, developed within Alloy's Genetic Medicines division, leverages novel oligonucleotide designs to enhance delivery, reduce inflammatory response, and improve performance relative to traditional antisense approaches.